Lancet interim results reveal 70% efficiency in Oxford-AstraZeneca vaccine

The COVID-19 vaccine developed by Oxford University- Astra Zeneca can protect against symptomatic diseases in 70 percent of the cases results published in The Lancet Journal suggests.

The COVID-19 vaccine developed by Oxford University- Astra Zeneca can protect against symptomatic diseases in 70 percent of the cases results published in The Lancet Journal suggests.

Its competitor, Moderna claims that its vaccines are 94 percent efficient and Pfizer vaccine has already got clearance from the UK government. However, none of them have published their trial results in a peer-reviewed scientific journal.

The Oxford trials revealed that their vaccine is 62 percent efficient if two full doses are given. Comparatively, the vaccine is 90 percent efficient if one and a half dose is given.

The study revealed, three participants out of 23,745, over an average of 3.4 months, experienced side effects.

Merryn Voysey, from Oxford University and one of the study authors, in a statement, said, “the results presented in this report provide the key findings from our first interim analysis. In future analyses, with more data included as it becomes available, we will investigate differences in key subgroups such as older adults, various ethnicities, doses, timing of booster vaccines and we will determine which immune responses equate to protection from infection or disease.”

In India, the vaccine is being produced and manufactured by SII and it has asked for emergency use approval from the central government.

Subscribe to our newsletter
Subscribe to our newsletter
Sign up here to get the latest news delivered directly to your inbox.
You can unsubscribe at any time